CompletedNCT07575516

Effectiveness of ashwagandha Extract in schizophrenia

It tested ashwagandha Extract for schizophrenia.

Schizophrenia, NeuroinflammationDrugFrom 20 Years to 45 Years

The study in practice

Understand this study

This study evaluated the effectiveness of Ashwagandha for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 20 years to 45 years. Other eligibility criteria applied.

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study start dateStarted: October 1, 2025

Recruitment status: Completed
Enrollment listed in the registry: 80
Sponsor: Hasanuddin University
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 2
Locations: Indonesia
Age range: From 20 Years to 45 Years
Official registry ID: NCT07575516
Official title: The Effectiveness of Ashwagandha Extract as an Adjuvant Therapy in Reducing Interleukin-1β Levels and Positive and Negative Syndrome Scale (PANSS) Scores in Schizophrenia Patients Receiving Risperidone

Completed

Makassar

FAQ

What did researchers investigate?

This study evaluated the effectiveness of Ashwagandha for people with schizophrenia.

Who is behind this study?

The study sponsor is Hasanuddin University, a university.

Did this study involve medication?

Yes. The study involved medication, including Risperidone 4mg/day and Ashwagandha.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 45 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.